|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treating Clostridium difficile Infection With Fecal Microbiota Transplantation显示文摘 | Johan S. Bakken Thomas Borody Lawrence J. Brandt Joel V. Brill Daniel C. Demarco Marc Alaric Franzos Colleen Kelly Alexander Khoruts Thomas Louie Lawrence P. Martinelli Thomas A. Moore George Russell Christina Surawicz | 2011 | Clinical Gastroenterology and Hepatology2011，，12： | 5 |
| 2 | Updates on treatment of irritable bowel syndrome显示文摘Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder characterized by abdominal pain and discomfort in association with altered bowel habits. It is estimated to affect 10%-15% of the Western population, and has a large impact on quality of life and (in)direct healthcare costs. IBS is a multifactorial disorder involving dysregulation within the brain-gut axis, and it is frequently associated with gastrointestinal motor and sensory dysfunction, enteric and central nervous system irregularities, neuroimmune dysregulation, and post- infectious inflammation. As with other functional medical disorders, the treatment for IBS can be challenging. Conventional therapy for those with moderate to severe symptoms is largely unsatisfactory, and the development of new and effective drugs is made difficult by the complex pathogenesis, variety of symptoms, and lack of objective clinical findings that are the hallmark of this disorder. Fortunately, research advances over the past several decades have provided insight into potential mechanisms responsible for the pathogenesis of IBS, and have led to the development of several promising pharmaceutical agents. In recent years there has been much publicity over several of these new IBS medications (alosetron and tegaserod) because of their reported association with ischemic colitis and cardiovascular disease. While these agents remain available for use under restricted prescribing programs, this highlights the need for continued development of safe and effective medication for IBS. This article provides a physiologically- based overview of recently developed and frequently employed pharmaceutical agents used to treat IBS, and discusses some non-pharmaceutical options that may be beneficial in this disorder. | Christopher W Hammerle Christina M Surawicz | 2008 | World Journal of Gastroenterology2008，14，17： | 4 |
| 3 | The Measurement of the Q-T Interval of the Electrocardiogram显示文摘 | EUGENE LEPESCHKIN BORYS SURAWICZ | 1952 | Circulation1952，，3： | 2 |
| 4 | Etiological role of mycobacterium in Crohn's disease: An assessment of the literature显示文摘 | Hubbard J Surawicz CM | 1999 | Dig Dis1999，17，1： | 1 |
| 5 | AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram,Part III:Intraventricular Conduction Disturbances显示文摘 | Surawicz B Childers R Deal B J | 2009 | Circulation2009，119，： | 1 |
| 6 | Probiotics, antibiotic-associated di- arrhoea and Clostridium difficile diarrhoea in humans 显示文摘 | SURAWICZ C M | 2003 | Best Practice & Research Clinical Gastroenterolo- gy2003，17，5： | 1 |
| 7 | U wave:facts,hypotheses,misconceptions,and misnomers显示文摘 | | 1998 | J Cardiovasc Electrophysiol1998，9，10： | 1 |
| 8 | Probiotics in the prevention and treatment of gastrointestinal infection显示文摘 | Huebner E S Surawicz C M | 2006 | Gastroenterol Clin North Am2006，35，2： | 1 |
| 9 | Probiotics, antibiotic-associated diarrhoea andclostridium difficile diarrhoea in humans显示文摘 | Surawicz CM | 2003 | Best Pract Res ClinGastroenterol2003，17，5： | 1 |
| 10 | Treating Clostridium difficile Infection With Fecal Microbiota Transplantation显示文摘 | Johan S. Bakken Thomas Borody Lawrence J. Brandt Joel V. Brill Daniel C. Demarco Marc Alaric Franzos Colleen Kelly Alexander Khoruts Thomas Louie Lawrence P. Martinelli Thomas A. Moore George Russell Christina Surawicz | 2011 | Clinical Gastroenterology and Hepatology2011，，12： | 1 |
| 11 | Guidelines for diagnosis,treatment,and prevention of clostridium difficile infections显示文摘 | Surawicz CM Brandt LJ Binion DG | 2013 | J Diabetes Complications2013，14，4： | 1 |
| 12 | Trends in incidence of primary brain tumors in the United States, 1985- 1994显示文摘 | Jukich P J McCarthy B J Surawicz T S | 2001 | Neuro Oncol2001，3，3： | 1 |
| 13 | Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections显示文摘 | Surawicz CM Brandt LJ Binion DG | 2013 | Am J Gastroenterol2013，108，： | 1 |
| 14 | U wave : Facts, hypotheses, misconceptions, and mis- nomers 显示文摘 | Surawicz B | 1998 | J Cardiovasc Electrophysiol1998，9，： | 1 |
| 15 | Descriptive epidemiology of primary brain and CNS tumors:results from the Central Brain Tumor Registry of the UnitedStates,1990 ~ 1994显示文摘 | Surawicz TS McCarthy BJ Kupelian V | | 0，，： | 1 |
| 16 | Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections 显示文摘 | Surawicz CM Brandt L J Binion DG | 2013 | Am J Gastroenterol2013，108，4： | 1 |
| 17 | AHA/ACCF/HRS Recom- mendations for the Standardization and Interpretation of the Electrocardio- gram: Part IV: The ST Segment, T and U Waves, and the QT Interval 显示文摘 | Pentti M Rautaharju Borys Surawicz | 2009 | Circulation2009，119，： | 1 |
| 18 | Treatment of refractory and recurrent Clostridium difficile infection显示文摘 | SURAWICZ CM ALEXANDER J | 2011 | Nat Rev Gastroenterol Hepatol2011，8，6： | 1 |
| 19 | Task force I:standardization of terminology and interpretation显示文摘 | Surawicz B Uhley H Borun B | 1978 | Am J Cardiol1978，41，： | 1 |
| 20 | Brain tumor survival: results from the National Cancer Data Base显示文摘 | Surawicz TS Davis F Freels S | 1998 | J Neurooncol1998，40，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员